Sale Kwon

Cooley advised AIM Intelligent Machines, the world’s first embodied artificial intelligence platform for earthmoving machinery, on its $50 million fundraise from various investors, including Khosla Ventures and General Catalyst. AIM will use the funding to transform the global construction and mining industries. Partner Sale Kwon led the Cooley team advising AIM.

Cooley assisted NCSOFT with its strategic investment in Emptyvessel. Partner Sale Kwon led the Cooley team advising NC West, NCSOFT’s North American subsidiary. NCSOFT, headquartered in Seoul, South Korea, is one of the top game publishers in the world.

Cooley advised DFJ Growth on its growth investment in Paradigm Health, a company on a mission to bring equitable access to clinical trials. This investment will bolster Paradigm’s innovative efforts and accelerate its growth trajectory. DFJ Growth is a venture capital firm that focuses on investing in innovative, high-growth companies. Lawyer Sale Kwon led the Cooley team advising DFJ Growth.

Cooley represented Wheeler Bio in the closing of its $35 million Series A-1 financing round. This funding will support Wheeler Bio’s ongoing efforts to expand its capabilities and accelerate the advancement of its partners’ therapies. Lawyers Sale Kwon and Emily Lee led the Cooley team advising Wheeler Bio, a developer of biomanufacturing services designed to translate therapeutic innovations into clinical impact.

Cooley represented Japanese-founded RegCell in its transition to being a US-based company in connection with the closing of $45.8 million of funding, consisting of $8.5 million in seed financing – co-led by The University of Tokyo Edge Capital Partners and Fast Track Initiative – and up to $37.3 million in nondilutive funding from Japan’s Agency for Medical Research and Development. Lawyers Dave Peinsipp, Sale Kwon and Yichen Liu led the Cooley team advising RegCell, a developer of cell therapies intended to treat autoimmune diseases and cancer.